

Disclosure of Value Transfers

Methodological Note

Country	Finland	
Entity Name	Fresenius Kabi Ab, sivuliike Suomessa Filial i Finland	
Legal Basis for Disclosure	Medicines for Europe Code of Conduct 2020, published February 2021	
Reporting Period	1.1.2024 - 31.12.2024	
Currency of disclosed values	All values are disclosed in	
uisciosca values	⊠ EUR	
	□ [local currency, if required]	
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to prescription-only medicines for human use.	
Value identification and Recognition	All values disclosed are based on value transfers actually made the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period.	
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.	
Data disclosed for	All values are disclosed for	
	☐ Recipients which have been engaged by entity	
	oximes Recipients which have their residence in the country (e.g. EFPIA and Medicines for Europe)	
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction	
Disclosure location:	https://www.fresenius-kabi.com/fi/resurssikeskus	

Annex Document No.: Version:

Date of Publication:

00

Date:

Page:



Disclosure of Value Transfers

Value category: "Meetings, educational	The company discloses value transfers in this category as per Option 2 of the MfE Transparency Requirements:
support and site visits of HCPs"	Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:
	• Sponsorship for attending a third party organised congress (as per section 6.1):
	- name of congress,
	- aggregated amount spent for the congress, including the
	- number of Healthcare Professionals financially supported to attend
	• Site visits (as per section 6.3): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
	• Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.
	Fees paid in connection with research & development activities or market research have not been disclosed.

Annex Document No.: Version: Date of Publication: Date:

Page: